clinical trials
-
Research updates, November 18
A new mechanistic study in Science Translational Medicine identifies Epstein-Barr virus (EBV) as a potential trigger of the autoimmune disease systemic lupus erythematosus.
-
Live blog: PolyBio’s Fall 2025 Symposium shares Long COVID and related disease research updates
Leading Long COVID and related disease researchers are set to present updates to their work today at the PolyBio Research Foundation’s Fall 2025 Symposium. PolyBio supports some of the most highly-anticipated research projects in infection-associated chronic conditions (IACCs).
-
Research updates, November 11
The RECOVER-NEURO clinical trial found that “cognitive rehabilitation” failed in treating Long COVID. The National Institutes of Health (NIH) study included 328 people who underwent interventions of either online cognitive training (computer games), a cognitive rehabilitation program, or received electric currents on their heads.
-
We need more at-home clinical trials for Long COVID. Here’s how we designed the largest one yet.
We are now recruiting for the Long COVID Treatment Trial-Tirzepatide (LoCITT-T), which participants can complete entirely from bed.
-
Metformin has been shown to reduce the risk of Long COVID. Why isn’t it more widely used?
Recent studies add evidence to a prior phase 3 clinical trial, suggesting that taking the diabetes drug during acute COVID-19 reduces the risk of long-term symptoms.
-
Research updates, October 28
A small mechanistic study in Frontiers in Immunology analyzed chronic inflammation in COVID-19. Researchers assessed over 70,000 blood cells from eight participants across different disease states.
-
Research updates, October 21
A clinical trial for the anti-inflammatory drug Colchicine did not find the drug effective for Long COVID, according to a new study published in JAMA Internal Medicine. The randomized trial included 346 participants in India who took at least 0.5 milligrams once or twice per day, or a placebo, for 52 weeks.
-
Vyvgart brought us back to life, but the Long COVID trial was canceled. We are calling on the NIH and HHS to study the drug.
We are a group of 53 individuals with Long COVID from across the U.S. In 2023, we joined a Long COVID clinical trial for Vyvgart (efgartigimod), a drug approved by the Food and Drug Administration (FDA) for the autoimmune disease myasthenia gravis. Without warning, the trial was canceled in June 2024.
-
Research updates, October 7
A new study that found the risk of Long COVID doubled in children following SARS-C0V-2 reinfection made mainstream headlines this week.
-
Research updates, September 30
Researchers in Spain assessed over 190,000 participants, using data from a public health research network, in a study published in the journal Vaccines. They found that Long COVID prevalence was three to 10 times higher in individuals with three or more reported infections than in those with only one infection.
Follow Us
get the latest long covid news
Trending
Recent ARTICLES
Tags
advocacy arts CDC clinical trials commentary COVID-19 precautions disability essay government policy H5N1 healthcare HHS influenza international Long COVID in children masks and respirators ME ME/CFS medical education national COVID-19 trends NIH NIH RECOVER podcast public health research update science Trump administration updates and events vaccines wastewater surveillance